TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983
TCL Archive Institute Of Medicine: External Experts Should Vet Large Projects, Report Says. June 20, 2003